Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2021 09:35 ET | Source: Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference

LB-100 is Currently in Clinical Studies for Four Cancer Targets: Phase 1b/2 for Myelodysplastic (MDS) SyndromesPhase 1b/2 for Advanced Soft Tissue SarcomaPhase 0 (Pharmacodynamics) for Glioblastoma...